Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Last updated: May 8, 2024
Sponsor: JeniVision, Inc.
Overall Status: Suspended

Phase

1/2

Condition

Williams Syndrome

Glaucoma

Stress

Treatment

JV-GL1

Latanoprost 0.005% Ophthalmic Solution

Clinical Study ID

NCT04761705
JV-GL1-OCU-GL-101/201-01
  • Ages > 18
  • All Genders

Study Summary

The aim of this research study is to assess the safety and feasibility of lowering intraocular pressure (IOP) using an experimental study drug, JV-GL1.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • bilateral open-angle glaucoma or ocular hypertension

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 70
Treatment Group(s): 2
Primary Treatment: JV-GL1
Phase: 1/2
Study Start date:
March 10, 2021
Estimated Completion Date:
July 31, 2025

Study Description

This is an open-label, dose escalation and dose expansion, study in adult participants with open-angle glaucoma or ocular hypertension. The study is divided into 2 parts:

Part 1 of the study is a dose escalation, sequentially testing escalating doses of JV-GL1.

Part 2 of the study will be randomized 2:2:1 (Experimental Dose A: Experimental Dose B: Active Control), treating additional subjects at the selected JV-GL1 doses or Latanoprost for 28 days.

Connect with a study center

  • Eye Research Foundation

    Newport Beach, California 92663
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.